2023年贝塞斯达系统对甲状腺细针穿刺抽吸物亚分类的实用性
UTILITY OF THE 2023 BETHESDA SYSTEM AUS SUBCATEGORIZATION ON THYROID ASPIRATES.
作者信息
Saharti S, Samargandy S
机构信息
"King Abdulaziz" University, Faculty of Medicine, Jeddah, Saudi Arabia.
出版信息
Acta Endocrinol (Buchar). 2024 Jan-Mar;20(1):1-4. doi: 10.4183/aeb.2024.1. Epub 2024 Oct 3.
Abstract
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is widely used for the standardized reporting of thyroid fine-needle aspiration (FNA) cytology. The 2023 revision of TBSRTC introduced specific subcategories for the classification of atypia of undetermined significance (AUS). This study tests the association between AUS subtypes and malignant diagnoses, namely AUS-nuclear atypia and AUS-other, in archived thyroid - FNA specimens with atypia from 2018-2022 at King Abdulaziz University Hospital. A total of 104 thyroid - FNA specimens with AUS were re-evaluated cytologically and correlated with subsequent surgical outcomes, along with a discussion of discrepant cases.
摘要
《贝塞斯达甲状腺细胞病理学报告系统》（TBSRTC）被广泛用于甲状腺细针穿刺（FNA）细胞学的标准化报告。TBSRTC的2023年修订版引入了意义未明的非典型性（AUS）分类的特定子类别。本研究在阿卜杜勒阿齐兹国王大学医院2018 - 2022年存档的具有非典型性的甲状腺FNA标本中，测试了AUS亚型与恶性诊断之间的关联，即AUS-核非典型性和AUS-其他。对总共104例具有AUS的甲状腺FNA标本进行了细胞学重新评估，并与随后的手术结果相关联，同时讨论了存在差异的病例。
相似文献
1
UTILITY OF THE 2023 BETHESDA SYSTEM AUS SUBCATEGORIZATION ON THYROID ASPIRATES.2023年贝塞斯达系统对甲状腺细针穿刺抽吸物亚分类的实用性
Acta Endocrinol (Buchar). 2024 Jan-Mar;20(1):1-4. doi: 10.4183/aeb.2024.1. Epub 2024 Oct 3.
2
A Comprehensive Approach to the Thyroid Bethesda Category III (AUS) in the Transition Zone Between 2nd Edition and 3rd Edition of The Bethesda System for Reporting Thyroid Cytopathology: Subcategorization, Nuclear Scoring, and More.《贝塞斯达系统报告甲状腺细胞病理学》第 2 版和第 3 版之间过渡区域甲状腺贝塞斯达类别 III（AUS）的综合方法：细分、核评分及更多。
Endocr Pathol. 2024 Mar;35(1):51-76. doi: 10.1007/s12022-024-09797-1. Epub 2024 Jan 27.
3
Impact of the 3rd Edition of the Bethesda System for Reporting Thyroid Cytopathology on Grey Zone Categories.第三版甲状腺细胞病理学报告贝塞斯达系统对灰色区域类别的影响。
Acta Cytol. 2023;67(6):593-603. doi: 10.1159/000534884. Epub 2023 Oct 28.
4
The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.应用亚分类和 BRAF 突变结果对甲状腺细胞病理学报告的 Bethesda 系统中“意义不明确的非典型性/滤泡性病变意义不明确”类别进行恶性风险预测。
Cancer Cytopathol. 2014 May;122(5):368-76. doi: 10.1002/cncy.21396. Epub 2014 Mar 3.
5
Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.不同的 AUS/FLUS 甲状腺细针穿刺活检的界限标准具有不同的 BRAF、RAS、RET/PTC 和 PAX8/PPARg 改变。
Cancer Cytopathol. 2018 May;126(5):317-325. doi: 10.1002/cncy.21984. Epub 2018 Feb 22.
6
The surgery and repeat aspiration outcomes of the atypia of undetermined significance/follicular lesion of undetermined significance category in The Bethesda System for Reporting Thyroid Cytopathology.《甲状腺细胞病理学报告系统-贝塞斯达系统》中不典型意义不明/滤泡性病变意义不明类别中手术和重复抽吸的结果。
Asian J Surg. 2019 Jan;42(1):144-147. doi: 10.1016/j.asjsur.2018.02.008. Epub 2018 Apr 11.
7
Unveiling Variations: A Comprehensive Comparison of Five Globally Used Thyroid Cytology Reporting Systems With Histopathological Correlation.揭示差异：五种全球常用甲状腺细胞病理学报告系统与组织病理学相关性的全面比较
Cureus. 2024 Feb 1;16(2):e53359. doi: 10.7759/cureus.53359. eCollection 2024 Feb.
8
Clinico-cytopathological subcategorization in thyroid nodules of atypia of undetermined significance/follicular lesion of undetermined significance using the TIRADS and Bethesda classifications.应用 TIRADS 和 Bethesda 分类对甲状腺不典型意义结节/滤泡性病变不明意义的良恶性进行临床-细胞病理亚分类。
Front Endocrinol (Lausanne). 2023 May 29;14:1135196. doi: 10.3389/fendo.2023.1135196. eCollection 2023.
9
Risk of malignancy in Thyroid "Atypia of undetermined significance/Follicular lesion of undetermined significance" and its subcategories - A 5-year experience.甲状腺“意义不明确的非典型性/意义不明确的滤泡性病变”及其亚类的恶性风险——一项5年的经验
Indian J Pathol Microbiol. 2019 Oct-Dec;62(4):544-548. doi: 10.4103/IJPM.IJPM_319_19.
10
Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China.贝塞斯达分类法第 III 类（AUS/FLUS）的再分类：基于中国国家癌症中心 ThinPrep 切片的甲状腺细针抽吸细胞学研究。
Cancer Cytopathol. 2021 Aug;129(8):642-648. doi: 10.1002/cncy.22417. Epub 2021 Jun 17.
本文引用的文献
1
Combined Afirma Genomic Sequencing Classifier and TERT promoter mutation detection in molecular assessment of Bethesda III-VI thyroid nodules.在贝塞斯达III - VI级甲状腺结节的分子评估中联合使用Afirma基因测序分类器和TERT启动子突变检测
Cancer Cytopathol. 2023 Oct;131(10):609-613. doi: 10.1002/cncy.22744. Epub 2023 Aug 6.
2
Clinico-cytopathological subcategorization in thyroid nodules of atypia of undetermined significance/follicular lesion of undetermined significance using the TIRADS and Bethesda classifications.应用 TIRADS 和 Bethesda 分类对甲状腺不典型意义结节/滤泡性病变不明意义的良恶性进行临床-细胞病理亚分类。
Front Endocrinol (Lausanne). 2023 May 29;14:1135196. doi: 10.3389/fendo.2023.1135196. eCollection 2023.
3
Hürthle cell-predominant thyroid fine needle aspiration cytology: A four risk-factor model highly accurate in excluding malignancy and predicting neoplasm.Hurthle 细胞为主型甲状腺细针抽吸细胞学检查：一种四因素模型，在排除恶性肿瘤和预测肿瘤方面具有高度准确性。
Diagn Cytopathol. 2022 Sep;50(9):424-435. doi: 10.1002/dc.25000. Epub 2022 Jun 8.
4
Subtype of atypia on cytology and risk of malignancy in pediatric thyroid nodules.儿童甲状腺结节细胞学非典型性的亚型与恶性风险
Cancer Cytopathol. 2022 May;130(5):330-335. doi: 10.1002/cncy.22544. Epub 2022 Feb 4.
5
Atypia of undetermined significance in thyroid cytology: Nuclear atypia and architectural atypia are associated with different molecular alterations and risks of malignancy.甲状腺细胞学中意义未明的非典型性：核非典型性和结构非典型性与不同的分子改变及恶性风险相关。
Cancer Cytopathol. 2021 Dec;129(12):966-972. doi: 10.1002/cncy.22495. Epub 2021 Aug 16.
6
Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.评价 BRAF、RAS、RET/PTC 和 PAX8/PPARγ 改变在不同 Bethesda 诊断分类中的情况：在意大利南部不同医院的 1172 例甲状腺细针抽吸活检标本中进行的 7 基因 panel 检测的有效性的多中心前瞻性研究。
Cancer Cytopathol. 2020 Feb;128(2):107-118. doi: 10.1002/cncy.22217. Epub 2019 Dec 10.
7
Risk of malignancy in Thyroid "Atypia of undetermined significance/Follicular lesion of undetermined significance" and its subcategories - A 5-year experience.甲状腺“意义不明确的非典型性/意义不明确的滤泡性病变”及其亚类的恶性风险——一项5年的经验
Indian J Pathol Microbiol. 2019 Oct-Dec;62(4):544-548. doi: 10.4103/IJPM.IJPM_319_19.
8
Trends in Thyroid Fine-Needle Aspiration Cytology Practices: Results From a College of American Pathologists 2016 Practice Survey.甲状腺细针穿刺细胞学检查实践的趋势：美国病理学家学院 2016 年实践调查的结果。
Arch Pathol Lab Med. 2019 Nov;143(11):1364-1372. doi: 10.5858/arpa.2018-0429-CP. Epub 2019 May 24.
9
A Proposal for Separation of Nuclear Atypia and Architectural Atypia in Bethesda Category III (AUS/FLUS) Based on Differing Rates of Thyroid Malignancy.基于甲状腺恶性肿瘤不同发生率的 Bethesda 分类系统Ⅲ类（AUS/FLUS）中核异型和结构异型的分离建议
Am J Clin Pathol. 2019 Jan 1;151(1):86-94. doi: 10.1093/ajcp/aqy109.
10
Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.不同的 AUS/FLUS 甲状腺细针穿刺活检的界限标准具有不同的 BRAF、RAS、RET/PTC 和 PAX8/PPARg 改变。
Cancer Cytopathol. 2018 May;126(5):317-325. doi: 10.1002/cncy.21984. Epub 2018 Feb 22.
Zotero 插件